botulinum toxin type A 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5368 None

Description:

MoleculeDescription

Synonyms:

  • botulinum toxin type A
  • nuceiva
  • incobotulinumtoxin A
  • NT 201
Botulinum toxin type A (Clostridium botulinum neurotoxin) blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within the nerve endings, thereby leading to denervation of the muscle and a flaccid paralysis.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 27, 2019 EMA Evolus Pharma Limited
Dec. 20, 2019 PMDA GlaxoSmithKline K.K.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 21939.63 21.11 13742 61280 805591 49724511
Product preparation error 9026.64 21.11 1918 73104 2454 50527648
Therapeutic response decreased 7344.17 21.11 2718 72304 44513 50485589
Eyelid ptosis 5275.01 21.11 1323 73699 4864 50525238
Off label use 4740.12 21.11 4545 70477 469881 50060221
Multiple use of single-use product 4405.72 21.11 835 74187 232 50529870
Wrong technique in product usage process 4318.52 21.11 1947 73075 53563 50476539
Injection site pain 2478.10 21.11 1712 73310 109312 50420790
Facial paresis 1407.90 21.11 405 74617 2747 50527355
Brow ptosis 1062.12 21.11 203 74819 67 50530035
Product preparation issue 1059.60 21.11 236 74786 425 50529677
Poor quality product administered 1025.50 21.11 309 74713 2510 50527592
Injection site swelling 799.22 21.11 588 74434 41185 50488917
Drug ineffective for unapproved indication 744.25 21.11 437 74585 20844 50509258
Dysphagia 713.06 21.11 717 74305 76801 50453301
Product storage error 672.70 21.11 339 74683 11885 50518217
Swelling face 649.48 21.11 573 74449 52022 50478080
Eye swelling 612.14 21.11 378 74644 19766 50510336
Muscular weakness 563.68 21.11 699 74323 94314 50435788
Eyelid oedema 490.19 21.11 252 74770 9214 50520888
Botulism 461.29 21.11 94 74928 79 50530023
Vision blurred 407.08 21.11 541 74481 78106 50451996
Facial paralysis 349.56 21.11 224 74798 12491 50517611
Therapeutic response shortened 343.44 21.11 183 74839 7206 50522896
Facial asymmetry 326.22 21.11 92 74930 574 50529528
Diarrhoea 321.48 21.11 243 74779 588233 49941869
Neck pain 306.67 21.11 400 74622 56667 50473435
Anaemia 299.48 21.11 19 75003 252437 50277665
Diplopia 293.41 21.11 237 74785 19023 50511079
Arthralgia 280.55 21.11 151 74871 438551 50091551
Neuromuscular toxicity 277.32 21.11 60 74962 87 50530015
Acute kidney injury 277.06 21.11 15 75007 228043 50302059
Headache 267.07 21.11 1463 73559 505072 50025030
Pneumonia 249.58 21.11 125 74897 378276 50151826
Influenza like illness 248.90 21.11 363 74659 57096 50473006
Skin tightness 244.72 21.11 117 74905 3646 50526456
Joint swelling 236.05 21.11 40 74982 245246 50284856
Migraine 227.91 21.11 404 74618 74876 50455226
Toxicity to various agents 217.40 21.11 29 74993 212470 50317632
Incorrect route of product administration 215.57 21.11 196 74826 18470 50511632
Injection site rash 215.08 21.11 184 74838 15993 50514109
Facial pain 213.97 21.11 136 74886 7473 50522629
Periorbital swelling 198.26 21.11 82 74940 1795 50528307
Rheumatoid arthritis 194.89 21.11 33 74989 202517 50327585
Contraindicated product administered 193.50 21.11 6 75016 148952 50381150
Neutropenia 192.07 21.11 6 75016 147959 50382143
Drug interaction 186.68 21.11 35 74987 199586 50330516
Eyelid sensory disorder 186.05 21.11 36 74986 15 50530087
Abdominal discomfort 184.59 21.11 57 74965 231584 50298518
Maternal exposure during pregnancy 183.60 21.11 14 75008 159764 50370338
Infusion related reaction 181.10 21.11 20 75002 169537 50360565
Product administered at inappropriate site 180.61 21.11 83 74939 2360 50527742
Hypotension 180.49 21.11 62 74960 235407 50294695
Lagophthalmos 178.13 21.11 48 74974 246 50529856
Injection site erythema 174.77 21.11 360 74662 74576 50455526
Systemic lupus erythematosus 174.66 21.11 8 75014 140614 50389488
Thrombocytopenia 174.07 21.11 3 75019 127670 50402432
Arthropathy 170.23 21.11 18 75004 157888 50372214
Fall 168.99 21.11 149 74873 334783 50195319
Completed suicide 168.86 21.11 6 75016 131883 50398219
Injection site mass 168.17 21.11 158 74864 15522 50514580
Hepatic enzyme increased 163.78 21.11 10 75012 137370 50392732
Product quality issue 155.96 21.11 210 74812 30648 50499454
Drug hypersensitivity 154.91 21.11 90 74932 250920 50279182
Death 150.99 21.11 156 74866 325223 50204879
Hypoaesthesia 149.12 21.11 471 74551 126786 50403316
Product distribution issue 147.70 21.11 51 74971 663 50529439
Peripheral swelling 146.46 21.11 61 74961 205875 50324227
Sepsis 146.26 21.11 14 75008 132911 50397191
General physical health deterioration 141.93 21.11 21 75001 142413 50387689
Blepharospasm 139.76 21.11 74 74948 2874 50527228
Glossodynia 139.00 21.11 8 75014 115561 50414541
Muscle twitching 138.40 21.11 141 74881 15290 50514812
Inappropriate schedule of product administration 135.59 21.11 317 74705 71514 50458588
Oedema peripheral 131.03 21.11 36 74986 157925 50372177
Infection 129.96 21.11 47 74975 172907 50357195
Swelling of eyelid 124.51 21.11 59 74963 1801 50528301
Condition aggravated 124.08 21.11 155 74867 296903 50233199
Renal failure 123.44 21.11 9 75013 106624 50423478
Injection site nodule 122.89 21.11 71 74951 3277 50526825
Wound 119.46 21.11 10 75012 105784 50424318
Incorrect dose administered 118.06 21.11 237 74785 48177 50481925
Abdominal pain 117.93 21.11 106 74916 236122 50293980
Haemoglobin decreased 117.39 21.11 23 74999 127193 50402909
Vomiting 116.79 21.11 326 74696 460432 50069670
Head discomfort 116.18 21.11 110 74912 10909 50519193
Periorbital oedema 115.21 21.11 79 74943 4933 50525169
Pyrexia 115.20 21.11 245 74777 379958 50150144
Nasopharyngitis 112.27 21.11 74 74948 192853 50337249
Muscle tightness 109.10 21.11 103 74919 10177 50519925
Hyponatraemia 108.78 21.11 9 75013 96130 50433972
Disease progression 108.40 21.11 9 75013 95857 50434245
Platelet count decreased 104.72 21.11 13 75009 100713 50429389
Dysphonia 104.07 21.11 198 74824 38694 50491408
Drug intolerance 103.85 21.11 103 74919 219001 50311101
Asthenopia 102.88 21.11 53 74969 1944 50528158
Injection site urticaria 101.23 21.11 107 74915 12110 50517992
Confusional state 100.71 21.11 77 74945 185851 50344251
Dry eye 99.30 21.11 174 74848 31921 50498181
Pain in extremity 98.39 21.11 158 74864 272707 50257395
Renal impairment 98.38 21.11 3 75019 75658 50454444
Eye pain 98.28 21.11 162 74860 28287 50501815
Hypertension 98.14 21.11 101 74921 211102 50319000
Weight increased 97.88 21.11 93 74929 201798 50328304
Hypokalaemia 97.48 21.11 9 75013 87983 50442119
Lacrimation increased 97.30 21.11 123 74899 16869 50513233
Pleural effusion 96.83 21.11 6 75016 81448 50448654
Fatigue 95.91 21.11 636 74386 706965 49823137
Injection site bruising 95.69 21.11 185 74837 36583 50493519
Gastrointestinal haemorrhage 95.00 21.11 3 75019 73318 50456784
Atrial fibrillation 94.69 21.11 18 75004 101727 50428375
Overdose 94.60 21.11 344 74678 99383 50430719
Stomatitis 94.17 21.11 18 75004 101326 50428776
Injection site paraesthesia 94.00 21.11 33 74989 452 50529650
Blood creatinine increased 92.40 21.11 5 75017 76155 50453947
Alopecia 89.17 21.11 141 74881 244906 50285196
Hypoaesthesia oral 88.96 21.11 94 74928 10634 50519468
Cough 87.62 21.11 139 74883 241125 50288977
Cardiac failure congestive 87.44 21.11 11 75011 84371 50445731
Lower respiratory tract infection 86.17 21.11 18 75004 95183 50434919
White blood cell count decreased 85.49 21.11 33 74989 116689 50413413
Decreased appetite 84.68 21.11 104 74918 200819 50329283
Treatment failure 83.89 21.11 50 74972 137587 50392515
Aspartate aminotransferase increased 83.73 21.11 9 75013 77989 50452113
Alanine aminotransferase increased 83.58 21.11 15 75007 88344 50441758
Pulmonary embolism 82.78 21.11 24 74998 101680 50428422
Dehydration 82.71 21.11 63 74959 152386 50377716
Cardiac failure 81.05 21.11 9 75013 76031 50454071
Impaired healing 80.44 21.11 6 75016 69780 50460322
Product dose omission issue 79.76 21.11 93 74929 183745 50346357
Cardiac arrest 79.56 21.11 14 75008 83637 50446465
Myocardial infarction 78.21 21.11 18 75004 89009 50441093
Pain 76.95 21.11 523 74499 578380 49951722
Gastrointestinal disorder 75.58 21.11 23 74999 94433 50435669
Neuropathy peripheral 74.86 21.11 25 74997 96732 50433370
Facial spasm 74.61 21.11 30 74992 609 50529493
Bronchitis 73.74 21.11 31 74991 104128 50425974
Intentional overdose 73.12 21.11 5 75017 62499 50467603
Drug abuse 72.37 21.11 4 75018 59842 50470260
Back pain 71.46 21.11 136 74886 219894 50310208
Speech disorder 70.47 21.11 160 74862 35388 50494714
Burning sensation 69.34 21.11 185 74837 45261 50484841
Product use issue 68.80 21.11 72 74950 149403 50380699
Paraesthesia 66.64 21.11 353 74669 119890 50410212
Injection site hypoaesthesia 66.49 21.11 24 74998 358 50529744
Deep vein thrombosis 66.04 21.11 14 75008 73290 50456812
Leukopenia 64.87 21.11 11 75011 67517 50462585
Urinary tract infection 64.72 21.11 148 74874 223872 50306230
Product reconstitution quality issue 63.58 21.11 15 75007 39 50530063
Exposure during pregnancy 63.12 21.11 52 74970 120963 50409139
Product packaging issue 62.67 21.11 30 74992 937 50529165
Coma 62.51 21.11 6 75016 56873 50473229
Patient dissatisfaction with treatment 62.26 21.11 15 75007 44 50530058
Sinusitis 62.12 21.11 98 74924 170460 50359642
Multiple organ dysfunction syndrome 62.02 21.11 3 75019 50334 50479768
Lid sulcus deepened 61.63 21.11 16 75006 69 50530033
Respiratory failure 61.61 21.11 29 74993 91152 50438950
Facial discomfort 61.55 21.11 14 75008 29 50530073
Blood glucose increased 61.50 21.11 15 75007 71309 50458793
Nausea 60.80 21.11 712 74310 704686 49825416
Hypoxia 60.06 21.11 4 75018 51119 50478983
Injection site oedema 59.05 21.11 30 74992 1068 50529034
Product temperature excursion issue 58.74 21.11 16 75006 86 50530016
Bradycardia 58.67 21.11 12 75010 64414 50465688
Neovascularisation 58.37 21.11 29 74993 984 50529118
Electrocardiogram QT prolonged 58.29 21.11 5 75017 51881 50478221
Hypoglycaemia 57.97 21.11 6 75016 53575 50476527
Septic shock 57.92 21.11 8 75014 57167 50472935
Mastication disorder 56.70 21.11 35 74987 1825 50528277
Paralysis 56.53 21.11 67 74955 8597 50521505
Ophthalmoplegia 56.17 21.11 31 74991 1309 50528793
Photophobia 55.81 21.11 88 74934 14799 50515303
Intentional product misuse 55.59 21.11 174 74848 46560 50483542
Suicide attempt 55.44 21.11 6 75016 51726 50478376
Blister 54.95 21.11 29 74993 85389 50444713
Drug effect less than expected 54.56 21.11 22 75000 450 50529652
Ocular discomfort 54.53 21.11 43 74979 3330 50526772
Pulmonary oedema 54.21 21.11 5 75017 48933 50481169
Liver function test abnormal 53.50 21.11 3 75019 44336 50485766
Constipation 53.36 21.11 123 74899 185585 50344517
Abnormal sensation in eye 53.04 21.11 32 74990 1601 50528501
Throat tightness 51.93 21.11 103 74919 20744 50509358
International normalised ratio increased 51.82 21.11 3 75019 43149 50486953
Eyelid pain 51.24 21.11 18 75004 247 50529855
Chronic obstructive pulmonary disease 50.68 21.11 9 75013 53426 50476676
Neutrophil count decreased 50.19 21.11 5 75017 46021 50484081
Oxygen saturation decreased 49.94 21.11 23 74999 73225 50456877
Central nervous system function test abnormal 49.64 21.11 9 75013 0 50530102
Injection site haemorrhage 49.06 21.11 102 74920 21244 50508858
Blood cholesterol increased 48.81 21.11 11 75011 55204 50474898
Hypoaesthesia eye 48.67 21.11 13 75009 64 50530038
C-reactive protein increased 48.31 21.11 19 75003 66455 50463647
Injection site discomfort 48.11 21.11 42 74980 3748 50526354
Eye discharge 48.11 21.11 48 74974 5075 50525027
Suspected product quality issue 47.72 21.11 16 75006 189 50529913
Thrombosis 47.63 21.11 12 75010 55821 50474281
Mucosal inflammation 47.57 21.11 3 75019 40139 50489963
Cardio-respiratory arrest 47.12 21.11 11 75011 53881 50476221
Irritable bowel syndrome 45.98 21.11 10 75012 51431 50478671
Lip swelling 45.36 21.11 108 74914 24628 50505474
Strabismus 44.81 21.11 30 74992 1800 50528302
Osteoporosis 43.79 21.11 7 75015 44872 50485230
Accidental exposure to product 43.73 21.11 102 74920 22955 50507147
Abdominal distension 43.67 21.11 27 74995 72876 50457226
Urticaria 43.55 21.11 335 74687 129226 50400876
Eye pruritus 42.78 21.11 71 74951 12463 50517639
Tension headache 42.41 21.11 34 74988 2697 50527405
Manufacturing product shipping issue 42.39 21.11 12 75010 76 50530026
Erythema of eyelid 42.38 21.11 29 74993 1804 50528298
Eye irritation 41.87 21.11 84 74938 17056 50513046
Fluid retention 41.11 21.11 12 75010 50637 50479465
Eyelid disorder 40.98 21.11 25 74997 1276 50528826
Depressed level of consciousness 40.92 21.11 13 75009 51940 50478162
Arthritis 40.76 21.11 41 74981 86680 50443422
Psoriatic arthropathy 40.33 21.11 10 75012 47022 50483080
Lung disorder 39.45 21.11 9 75013 44790 50485312
Haematochezia 39.42 21.11 6 75016 39876 50490226
Agitation 39.22 21.11 15 75007 53369 50476733
Diabetes mellitus 39.10 21.11 12 75010 49021 50481081
Muscle contractions involuntary 38.84 21.11 28 74994 1894 50528208
Skin indentation 38.84 21.11 9 75013 21 50530081
Ocular hyperaemia 38.73 21.11 90 74932 20202 50509900
Skin wrinkling 38.59 21.11 21 75001 862 50529240
Femur fracture 38.52 21.11 5 75017 37459 50492643
Injection site indentation 38.44 21.11 13 75009 158 50529944
Dyspnoea exertional 38.30 21.11 14 75008 51219 50478883
Muscle atrophy 37.75 21.11 46 74976 6075 50524027
Osteoarthritis 37.63 21.11 28 74994 68578 50461524
Colitis 37.62 21.11 6 75016 38523 50491579
Blood pressure increased 37.56 21.11 89 74933 133043 50397059
Ill-defined disorder 37.51 21.11 17 75005 54637 50475465
Delirium 37.17 21.11 6 75016 38186 50491916
Prescribed overdose 36.20 21.11 72 74950 14528 50515574
White blood cell count increased 36.18 21.11 9 75013 42231 50487871
Madarosis 35.82 21.11 30 74992 2530 50527572
Injection site pruritus 35.44 21.11 136 74886 40275 50489827
Hepatitis 35.41 21.11 3 75019 31450 50498652
Cataract 35.24 21.11 13 75009 47287 50482815
Epistaxis 35.21 21.11 26 74996 63928 50466174
Pancreatitis 34.76 21.11 10 75012 42604 50487498
Post-traumatic neck syndrome 34.48 21.11 26 74996 1884 50528218
Chest pain 34.47 21.11 140 74882 176742 50353360
Vertigo 34.24 21.11 160 74862 51672 50478430
Knee arthroplasty 34.07 21.11 6 75016 35840 50494262
Rhabdomyolysis 34.05 21.11 8 75014 39019 50491083
Hip arthroplasty 33.99 21.11 3 75019 30426 50499676
Hepatic failure 33.94 21.11 4 75018 32279 50497823
Liver disorder 33.74 21.11 7 75015 37215 50492887
Red blood cell count decreased 33.65 21.11 5 75017 33830 50496272
Blood bilirubin increased 33.61 21.11 4 75018 32034 50498068
Muscle injury 33.60 21.11 7 75015 37104 50492998
Nerve injury 33.60 21.11 51 74971 8299 50521803
Blood pressure systolic increased 33.55 21.11 6 75016 35443 50494659
Hospitalisation 33.22 21.11 31 74991 67906 50462196
Mobility decreased 32.99 21.11 42 74980 79906 50450196
Choking 32.92 21.11 51 74971 8447 50521655
Gamma-glutamyltransferase increased 32.88 21.11 3 75019 29620 50500482
Pneumonitis 32.72 21.11 3 75019 29507 50500595
Mental status changes 32.52 21.11 7 75015 36265 50493837
Lip disorder 32.35 21.11 21 75001 1196 50528906
Pregnancy 32.33 21.11 107 74915 29470 50500632
Blood alkaline phosphatase increased 32.13 21.11 8 75014 37518 50492584
Libido increased 31.94 21.11 21 75001 1222 50528880
Wheezing 31.92 21.11 27 74995 62020 50468082
Rectal haemorrhage 31.54 21.11 9 75013 38549 50491553
Cutis laxa 31.38 21.11 11 75011 150 50529952
Haematocrit decreased 30.85 21.11 7 75015 34969 50495133
Application site acne 30.67 21.11 6 75016 3 50530099
Blood pressure decreased 30.42 21.11 23 74999 55886 50474216
Haemorrhage 30.37 21.11 21 75001 53420 50476682
Injection site anaesthesia 30.36 21.11 8 75014 37 50530065
Injection site inflammation 30.04 21.11 30 74992 3175 50526927
Oedema 29.87 21.11 36 74986 70145 50459957
Injury 29.47 21.11 18 75004 48907 50481195
Somnolence 29.36 21.11 124 74898 154861 50375241
Encephalopathy 29.23 21.11 7 75015 33704 50496398
Skin disorder 29.05 21.11 90 74932 23940 50506162
Hypocalcaemia 29.01 21.11 3 75019 26813 50503289
Rash maculo-papular 28.77 21.11 3 75019 26638 50503464
Treatment noncompliance 28.76 21.11 5 75017 30145 50499957
Psoriasis 28.73 21.11 36 74986 68964 50461138
Soft tissue injury 28.58 21.11 21 75001 1463 50528639
Jaundice 28.48 21.11 3 75019 26426 50503676
Vestibular migraine 28.18 21.11 11 75011 206 50529896
Muscle spasms 28.00 21.11 297 74725 125256 50404846
Injection site pallor 27.95 21.11 8 75014 53 50530049
Haematemesis 27.79 21.11 4 75018 27721 50502381
Dry mouth 27.79 21.11 160 74862 56018 50474084
Intranasal hypoaesthesia 27.58 21.11 5 75017 0 50530102
Injection site alopecia 27.58 21.11 5 75017 0 50530102
Skin ulcer 27.52 21.11 9 75013 35309 50494793
Pericardial effusion 27.33 21.11 3 75019 25586 50504516
Haemoptysis 27.31 21.11 3 75019 25570 50504532
Hostility 27.28 21.11 22 75000 1760 50528342
Erythema 27.10 21.11 334 74688 146080 50384022
Eye contusion 27.01 21.11 21 75001 1593 50528509
Drooling 26.90 21.11 29 74993 3355 50526747
Malaise 26.72 21.11 344 74678 335188 50194914
Diverticulitis 26.67 21.11 8 75014 33174 50496928
Sensation of foreign body 26.61 21.11 31 74991 3905 50526197
Eyelid thickening 26.43 21.11 8 75014 66 50530036
Cellulitis 26.40 21.11 40 74982 70758 50459344
Diaphragmatic rupture 26.29 21.11 11 75011 248 50529854
Serotonin syndrome 26.14 21.11 3 75019 24710 50505392
Intestinal obstruction 26 21.11 4 75018 26379 50503723
Gastric disorder 25.89 21.11 6 75016 29542 50500560
Injection site haematoma 25.79 21.11 38 74984 6022 50524080
Flatulence 25.77 21.11 6 75016 29452 50500650
Angina pectoris 25.74 21.11 4 75018 26184 50503918
Torticollis 25.66 21.11 21 75001 1715 50528387
Rash 25.51 21.11 476 74546 436995 50093107
Product supply issue 25.45 21.11 18 75004 1181 50528921
Dermatochalasis 25.23 21.11 5 75017 3 50530099
Blepharochalasis 25.23 21.11 5 75017 3 50530099
Injection site scab 25.21 21.11 12 75010 370 50529732
Abdominal pain upper 25.18 21.11 136 74886 159173 50370929
Paradoxical drug reaction 25.12 21.11 29 74993 3618 50526484
Pancreatitis acute 24.91 21.11 3 75019 23809 50506293
Localised infection 24.81 21.11 4 75018 25481 50504621
Upper respiratory tract infection 24.79 21.11 37 74985 65861 50464241
Drug specific antibody 24.74 21.11 21 75001 1804 50528298
Vascular malformation 24.63 21.11 11 75011 292 50529810
Cerebrovascular accident 24.60 21.11 66 74956 94614 50435488
Eyelids pruritus 24.39 21.11 15 75007 777 50529325
Full blood count abnormal 24.34 21.11 3 75019 23385 50506717
Product quality control issue 24.33 21.11 6 75016 20 50530082
Mouth ulceration 23.94 21.11 6 75016 28018 50502084
Red blood cell sedimentation rate increased 23.81 21.11 7 75015 29409 50500693
Visual impairment 23.74 21.11 178 74844 68097 50462005
Dysarthria 23.64 21.11 114 74908 37289 50492813
Eyelid function disorder 23.60 21.11 10 75012 233 50529869
Hepatic steatosis 23.35 21.11 4 75018 24380 50505722
Sternal fracture 23.06 21.11 21 75001 1981 50528121
Gastritis 23.04 21.11 10 75012 32973 50497129
Application site papules 22.99 21.11 7 75015 59 50530043
Urinary retention 22.85 21.11 88 74934 26102 50504000
Cholelithiasis 22.83 21.11 14 75008 37959 50492143
Dyspnoea 22.82 21.11 628 74394 546980 49983122
Tachycardia 22.69 21.11 74 74948 99689 50430413
Injection site granuloma 22.07 21.11 6 75016 32 50530070
Injection site vesicles 21.90 21.11 23 74999 2582 50527520
Acute myocardial infarction 21.88 21.11 8 75014 29265 50500837
Feeling abnormal 21.82 21.11 283 74739 125209 50404893
Injection site discolouration 21.81 21.11 38 74984 6936 50523166
Blood potassium decreased 21.69 21.11 14 75008 36931 50493171
Paranasal cyst 21.64 21.11 10 75012 288 50529814
Gastric ulcer 21.53 21.11 3 75019 21302 50508800
Muscle hypertrophy 21.49 21.11 7 75015 75 50530027
Weight decreased 21.44 21.11 217 74805 221028 50309074
Productive cough 21.41 21.11 28 74994 52666 50477436
Pulmonary fibrosis 21.33 21.11 5 75017 24432 50505670
Blood sodium decreased 21.32 21.11 3 75019 21144 50508958

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 2288.31 25.67 1416 8368 361754 29202989
Off label use 922.44 25.67 767 9017 300033 29264710
Product preparation error 864.60 25.67 180 9604 1482 29563261
Therapeutic response decreased 640.50 25.67 257 9527 24454 29540289
Multiple use of single-use product 475.40 25.67 79 9705 136 29564607
Wrong technique in product usage process 388.79 25.67 195 9589 31233 29533510
Eyelid ptosis 383.65 25.67 118 9666 5068 29559675
Injection site pain 379.99 25.67 194 9590 32252 29532491
Dysphagia 243.09 25.67 176 9608 54750 29509993
Muscular weakness 198.39 25.67 164 9620 61888 29502855
Product storage error 132.37 25.67 57 9727 6413 29558330
Product preparation issue 118.00 25.67 25 9759 224 29564519
Migraine 115.97 25.67 64 9720 12366 29552377
Botulism 109.40 25.67 22 9762 148 29564595
Poor quality product administered 107.72 25.67 34 9750 1585 29563158
Neuromuscular toxicity 93.09 25.67 16 9768 37 29564706
Injection site swelling 67.86 25.67 41 9743 9376 29555367
Neck pain 64.85 25.67 55 9729 21392 29543351
Acute kidney injury 60.92 25.67 8 9776 265259 29299484
Facial paresis 59.75 25.67 25 9759 2616 29562127
Headache 59.61 25.67 158 9626 173849 29390894
Brow ptosis 56.12 25.67 8 9776 0 29564743
Drug ineffective for unapproved indication 52.56 25.67 41 9743 14173 29550570
Anaemia 48.74 25.67 5 9779 200946 29363797
Head discomfort 45.56 25.67 22 9762 3220 29561523
Diplopia 41.53 25.67 35 9749 13483 29551260
Nightmare 40.20 25.67 32 9752 11385 29553358
Therapeutic product effect decreased 38.36 25.67 48 9736 29403 29535340
Drug interaction 36.69 25.67 10 9774 197375 29367368
Injection site rash 35.01 25.67 19 9765 3545 29561198
Toxicity to various agents 33.81 25.67 8 9776 173653 29391090
Nephrolithiasis 32.53 25.67 41 9743 25293 29539450
Urinary retention 30.88 25.67 45 9739 31853 29532890
Sedation 30.41 25.67 33 9751 17372 29547371
Diarrhoea 28.82 25.67 41 9743 332657 29232086
Residual urine volume increased 28.06 25.67 4 9780 0 29564743
Eyelid oedema 27.88 25.67 18 9766 4618 29560125
Thrombocytopenia 26.64 25.67 6 9778 134817 29429926
Aspiration 26.52 25.67 24 9760 10156 29554587
Product distribution issue 25.87 25.67 8 9776 348 29564395

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 8970.66 21.42 6396 45619 833851 63612866
Product preparation error 5083.62 21.42 1058 50957 2947 64443770
Eyelid ptosis 3269.19 21.42 872 51143 8653 64438064
Off label use 2942.06 21.42 3031 48984 629775 63816942
Therapeutic response decreased 2895.74 21.42 1206 50809 50982 64395735
Wrong technique in product usage process 2138.50 21.42 1043 50972 63931 64382786
Multiple use of single-use product 1895.69 21.42 341 51674 261 64446456
Injection site pain 1682.39 21.42 1071 50944 110337 64336380
Facial paresis 833.51 21.42 260 51755 4632 64442085
Brow ptosis 705.89 21.42 123 51892 58 64446659
Dysphagia 698.59 21.42 623 51392 106189 64340528
Muscular weakness 565.98 21.42 601 51414 126737 64319980
Injection site swelling 554.84 21.42 370 51645 40983 64405734
Poor quality product administered 548.18 21.42 171 51844 3044 64443673
Product preparation issue 527.15 21.42 122 51893 622 64446095
Drug ineffective for unapproved indication 520.40 21.42 320 51695 30813 64415904
Swelling face 488.77 21.42 395 51620 58771 64387946
Eye swelling 442.59 21.42 256 51759 22025 64424692
Migraine 414.07 21.42 368 51647 62309 64384408
Headache 398.58 21.42 1127 50888 528340 63918377
Botulism 392.20 21.42 84 51931 277 64446440
Product storage error 390.10 21.42 198 51817 13120 64433597
Vision blurred 368.93 21.42 408 51607 89908 64356809
Eyelid oedema 352.21 21.42 180 51835 12099 64434618
Neck pain 339.92 21.42 327 51688 61206 64385511
Neuromuscular toxicity 301.26 21.42 61 51954 139 64446578
Acute kidney injury 294.43 21.42 17 51998 449223 63997494
Therapeutic response shortened 245.89 21.42 133 51882 10037 64436680
Anaemia 237.22 21.42 18 51997 378662 64068055
Diplopia 232.14 21.42 184 51831 26581 64420136
Influenza like illness 220.09 21.42 260 51755 61442 64385275
Facial paralysis 203.38 21.42 148 51867 18818 64427899
Toxicity to various agents 202.45 21.42 27 51988 363486 64083231
Facial asymmetry 192.95 21.42 54 51961 645 64446072
Incorrect route of product administration 191.04 21.42 155 51860 23143 64423574
Drug interaction 189.90 21.42 32 51983 362051 64084666
Injection site rash 178.30 21.42 127 51888 15615 64431102
Hypoaesthesia 172.52 21.42 360 51655 138748 64307969
Facial pain 168.21 21.42 95 51920 7800 64438917
Neutropenia 166.75 21.42 6 52009 239618 64207099
Skin tightness 163.70 21.42 80 51935 4881 64441836
Pneumonia 163.00 21.42 128 51887 559448 63887269
Completed suicide 162.03 21.42 4 52011 224410 64222307
Injection site erythema 159.16 21.42 238 51777 70562 64376155
Head discomfort 149.28 21.42 102 51913 11732 64434985
Injection site mass 148.18 21.42 118 51897 17152 64429565
Diarrhoea 145.88 21.42 224 51791 722480 63724237
Thrombocytopenia 144.78 21.42 9 52006 223792 64222925
Hypotension 143.41 21.42 64 51951 380910 64065807
Eyelid sensory disorder 131.87 21.42 23 51992 11 64446706
Muscle tightness 124.32 21.42 89 51926 11026 64435691
Product quality issue 123.88 21.42 136 51879 29663 64417054
Periorbital swelling 119.48 21.42 48 51967 1828 64444889
Injection site nodule 115.38 21.42 55 51960 3175 64443542
Lagophthalmos 114.61 21.42 31 51984 323 64446394
Blepharospasm 113.08 21.42 55 51960 3320 64443397
Paraesthesia 109.93 21.42 296 51719 134226 64312491
Asthenopia 108.73 21.42 46 51969 2001 64444716
Muscle twitching 108.66 21.42 103 51912 18895 64427822
Arthralgia 107.59 21.42 119 51896 442141 64004576
Renal failure 107.22 21.42 11 52004 181677 64265040
Sepsis 106.93 21.42 27 51988 230314 64216403
Dry eye 102.94 21.42 122 51893 28897 64417820
Injection site bruising 102.06 21.42 136 51879 36237 64410480
General physical health deterioration 100.79 21.42 21 51994 204404 64242313
Dysphonia 98.65 21.42 152 51863 46230 64400487
Product administered at inappropriate site 96.21 21.42 48 51967 3062 64443655
Renal impairment 91.77 21.42 4 52011 135013 64311704
Injection site urticaria 90.83 21.42 74 51941 11107 64435610
Eye pain 89.88 21.42 119 51896 31506 64415211
Hypoaesthesia oral 88.55 21.42 74 51941 11506 64435211
Haemoglobin decreased 88.36 21.42 24 51991 195039 64251678
Blood creatinine increased 86.18 21.42 6 52009 135776 64310941
Joint swelling 86.08 21.42 33 51982 215349 64231368
Platelet count decreased 85.24 21.42 16 51999 167695 64279022
Product distribution issue 84.48 21.42 30 51985 808 64445909
Atrial fibrillation 83.45 21.42 18 51997 171071 64275646
Oedema peripheral 82.77 21.42 33 51982 210284 64236433
Hepatic enzyme increased 81.73 21.42 6 52009 129937 64316780
Infusion related reaction 80.84 21.42 17 51998 164450 64282267
Cardiac failure congestive 79.42 21.42 7 52008 130573 64316144
Gastrointestinal haemorrhage 78.07 21.42 8 52007 132304 64314413
Prescribed overdose 78.00 21.42 89 51926 20242 64426475
Disease progression 77.61 21.42 11 52004 141669 64305048
Periorbital oedema 77.53 21.42 57 51958 7357 64439360
Injection site paraesthesia 76.88 21.42 25 51990 511 64446206
Hyponatraemia 75.70 21.42 14 52001 148325 64298392
Swelling of eyelid 74.28 21.42 36 51979 2156 64444561
Myocardial infarction 73.97 21.42 21 51994 165800 64280917
Fall 73.89 21.42 140 51875 416686 64030031
Cardiac arrest 73.54 21.42 17 51998 154047 64292670
Neovascularisation 72.94 21.42 29 51986 1074 64445643
Pleural effusion 71.29 21.42 9 52006 126550 64320167
Pyrexia 71.20 21.42 223 51792 558421 63888296
Cardiac failure 70.84 21.42 11 52004 132362 64314355
Speech disorder 69.09 21.42 133 51882 48308 64398409
Injection site haemorrhage 66.91 21.42 90 51925 24188 64422529
Drug abuse 66.47 21.42 13 52002 132361 64314356
Alanine aminotransferase increased 65.06 21.42 16 51999 139015 64307702
Infection 63.50 21.42 35 51980 184845 64261872
Hypokalaemia 63.29 21.42 11 52004 121892 64324825
Burning sensation 63.19 21.42 130 51885 49534 64397183
Arthropathy 62.62 21.42 11 52004 120956 64325761
Product packaging issue 62.15 21.42 25 51990 955 64445762
Confusional state 61.51 21.42 72 51943 261072 64185645
Aspartate aminotransferase increased 59.64 21.42 12 52003 119776 64326941
Throat tightness 59.51 21.42 83 51932 23077 64423640
Muscle spasms 58.47 21.42 247 51768 140776 64305941
Contraindicated product administered 57.60 21.42 9 52006 107820 64338897
Abdominal pain 57.01 21.42 103 51912 312272 64134445
Lacrimation increased 56.76 21.42 72 51943 18274 64428443
Dehydration 56.35 21.42 55 51960 216708 64230009
Rheumatoid arthritis 55.13 21.42 32 51983 164262 64282455
Central nervous system function test abnormal 55.11 21.42 9 52006 0 64446717
Intentional overdose 54.21 21.42 5 52010 89939 64356778
Multiple organ dysfunction syndrome 52.97 21.42 9 52006 101404 64345313
Injection site discomfort 52.17 21.42 36 51979 4205 64442512
Decreased appetite 51.99 21.42 92 51923 281197 64165520
Condition aggravated 51.47 21.42 143 51872 372283 64074434
Maternal exposure during pregnancy 51.22 21.42 8 52007 95876 64350841
Overdose 51.01 21.42 259 51756 159307 64287410
Photophobia 50.57 21.42 66 51949 17227 64429490
White blood cell count decreased 49.83 21.42 33 51982 157804 64288913
Hypertension 49.55 21.42 83 51932 259178 64187539
Ocular discomfort 49.32 21.42 34 51981 3965 64442752
Post-traumatic neck syndrome 49.13 21.42 26 51989 1876 64444841
Bradycardia 49.09 21.42 17 51998 118202 64328515
Strabismus 49.02 21.42 27 51988 2110 64444607
Mastication disorder 48.98 21.42 28 51987 2351 64444366
International normalised ratio increased 48.80 21.42 4 52011 79163 64367554
Leukopenia 48.65 21.42 11 52004 101231 64345486
Neuropathy peripheral 48.63 21.42 17 51998 117508 64329209
Pulmonary embolism 48.40 21.42 29 51986 146327 64300390
Ophthalmoplegia 48.25 21.42 29 51986 2673 64444044
Death 48.14 21.42 213 51802 482492 63964225
Urticaria 47.71 21.42 240 51775 147077 64299640
Abdominal discomfort 47.68 21.42 46 51969 182276 64264441
Eye irritation 47.12 21.42 61 51954 15795 64430922
Peripheral swelling 46.77 21.42 60 51955 209093 64237624
Electrocardiogram QT prolonged 46.35 21.42 5 52010 79443 64367274
Drug effect less than expected 46.14 21.42 17 51998 510 64446207
Erythema of eyelid 45.52 21.42 25 51990 1943 64444774
Suicide attempt 45.45 21.42 3 52012 71004 64375713
Product reconstitution quality issue 45.23 21.42 13 52002 172 64446545
Systemic lupus erythematosus 44.99 21.42 5 52010 77607 64369110
Dry mouth 44.41 21.42 128 51887 60290 64386427
Feeling abnormal 44.20 21.42 219 51796 133383 64313334
Eye discharge 44.16 21.42 35 51980 5049 64441668
Rhabdomyolysis 44.00 21.42 10 52005 91716 64355001
Patient dissatisfaction with treatment 43.86 21.42 12 52003 131 64446586
Injection site oedema 43.55 21.42 20 51995 1060 64445657
Pulmonary oedema 43.33 21.42 6 52009 78668 64368049
Manufacturing product shipping issue 43.15 21.42 11 52004 89 64446628
Drug hypersensitivity 42.84 21.42 79 51936 237736 64208981
Hypoglycaemia 42.72 21.42 10 52005 89882 64356835
Nerve injury 42.68 21.42 41 51974 7644 64439073
Septic shock 42.35 21.42 16 51999 105421 64341296
Facial spasm 42.12 21.42 17 51998 655 64446062
Accidental exposure to product 42.10 21.42 76 51939 26288 64420429
Stomatitis 41.79 21.42 18 51997 109587 64337130
Vomiting 41.69 21.42 267 51748 550850 63895867
Paralysis 41.53 21.42 49 51966 11546 64435171
Vertigo 41.44 21.42 123 51892 58888 64387829
Coma 41.14 21.42 10 52005 87605 64359112
Weight increased 41.03 21.42 68 51947 213280 64233437
Abnormal sensation in eye 40.11 21.42 22 51993 1705 64445012
Metabolic acidosis 40.06 21.42 5 52010 70953 64375764
Neutrophil count decreased 39.99 21.42 7 52008 77189 64369528
Tension headache 39.93 21.42 28 51987 3355 64443362
Eye pruritus 39.66 21.42 50 51965 12609 64434108
Hypoxia 39.60 21.42 11 52004 88138 64358579
Soft tissue injury 39.14 21.42 21 51994 1558 64445159
Pericarditis 38.97 21.42 3 52012 62513 64384204
Agitation 37.92 21.42 12 52003 88355 64358362
Injection site pruritus 37.91 21.42 90 51925 37736 64408981
Hepatic function abnormal 37.64 21.42 4 52011 64309 64382408
Blood glucose increased 37.56 21.42 16 51999 98057 64348660
Endometriosis 37.44 21.42 25 51990 2767 64443950
Wound 37.36 21.42 8 52007 76469 64370248
Cough 36.72 21.42 123 51892 302025 64144692
Libido increased 36.67 21.42 21 51994 1769 64444948
Cardio-respiratory arrest 36.20 21.42 17 51998 98376 64348341
Inappropriate schedule of product administration 36.19 21.42 159 51856 92127 64354590
Drug specific antibody 36.16 21.42 22 51993 2073 64444644
Injection site haematoma 36.14 21.42 28 51987 3908 64442809
Ocular hyperaemia 35.97 21.42 65 51950 22499 64424218
Muscle spasticity 35.95 21.42 55 51960 16614 64430103
Lip swelling 35.38 21.42 79 51936 31828 64414889
Choking 35.23 21.42 43 51972 10495 64436222
Hostility 35.10 21.42 22 51993 2185 64444532
Injection site hypoaesthesia 34.97 21.42 13 52002 400 64446317
Visual impairment 34.86 21.42 135 51880 73942 64372775
Nasopharyngitis 34.54 21.42 66 51949 196007 64250710
Application site acne 34.31 21.42 6 52009 3 64446714
Product temperature excursion issue 34.07 21.42 9 52006 85 64446632
Diaphragmatic rupture 34.05 21.42 11 52004 220 64446497
Lid sulcus deepened 33.88 21.42 10 52005 146 64446571
Colitis 33.45 21.42 4 52011 58670 64388047
Deep vein thrombosis 33.17 21.42 22 51993 105160 64341557
Dermatochalasis 32.59 21.42 6 52009 6 64446711
Dizziness 32.54 21.42 507 51508 429656 64017061
Lower respiratory tract infection 32.34 21.42 18 51997 94596 64352121
Haematochezia 32.31 21.42 7 52008 66366 64380351
Sternal fracture 32.27 21.42 21 51994 2226 64444491
Eyelid pain 32.01 21.42 11 52004 268 64446449
Injection site inflammation 31.97 21.42 24 51991 3197 64443520
Rectal haemorrhage 31.17 21.42 6 52009 61811 64384906
Vascular malformation 31.16 21.42 11 52004 291 64446426
C-reactive protein increased 31.10 21.42 19 51996 94890 64351827
Paradoxical drug reaction 30.91 21.42 31 51984 6089 64440628
Respiratory failure 30.40 21.42 52 51963 161131 64285586
Cerebral haemorrhage 30.36 21.42 3 52012 51087 64395630
Epistaxis 30.31 21.42 21 51994 98110 64348607
Impaired healing 30.21 21.42 6 52009 60467 64386250
Chronic obstructive pulmonary disease 29.86 21.42 10 52005 71038 64375679
Liver function test abnormal 29.46 21.42 6 52009 59395 64387322
Madarosis 29.18 21.42 20 51995 2310 64444407
Injection site indentation 29.01 21.42 9 52006 157 64446560
Acute myocardial infarction 28.98 21.42 10 52005 69708 64377009
Delirium 28.63 21.42 10 52005 69184 64377533
Lung disorder 28.35 21.42 7 52008 60693 64386024
Eyelid contusion 28.27 21.42 5 52010 3 64446714
Blood bilirubin increased 28.15 21.42 6 52009 57547 64389170
Vitreous floaters 28.07 21.42 30 51985 6343 64440374
Thrombosis 27.90 21.42 11 52004 70631 64376086
Drug-induced liver injury 27.78 21.42 3 52012 47640 64399077
Bronchitis 27.76 21.42 28 51987 108715 64338002
Anxiety 27.60 21.42 267 51748 202382 64244335
Rash maculo-papular 27.33 21.42 3 52012 47023 64399694
Eyelid disorder 27.23 21.42 16 51999 1415 64445302
Depressed level of consciousness 27.10 21.42 16 51999 81420 64365297
Diabetes mellitus 26.84 21.42 10 52005 66464 64380253
Mental status changes 26.79 21.42 8 52007 61154 64385563
Skin wrinkling 26.78 21.42 14 52001 985 64445732
Haemoptysis 26.40 21.42 4 52011 49044 64397673
Lip disorder 26.39 21.42 15 52000 1246 64445471
Paranasal cyst 26.13 21.42 10 52005 334 64446383
Angina pectoris 25.88 21.42 3 52012 45078 64401639
Product quality control issue 25.85 21.42 5 52010 8 64446709
Fluid retention 25.74 21.42 8 52007 59598 64387119
Glossodynia 25.67 21.42 10 52005 64686 64382031
Transaminases increased 25.52 21.42 3 52012 44591 64402126
Blood alkaline phosphatase increased 25.32 21.42 7 52008 56272 64390445
Product dose omission issue 25.23 21.42 77 51938 194670 64252047
Liver disorder 25.22 21.42 6 52009 53345 64393372
Blood urea increased 25.20 21.42 3 52012 44150 64402567
Unresponsive to stimuli 25.18 21.42 5 52010 50388 64396329
Eye contusion 24.96 21.42 17 51998 1944 64444773
Haematemesis 24.92 21.42 4 52011 46995 64399722
Treatment noncompliance 24.70 21.42 3 52012 43479 64403238
Intranasal hypoaesthesia 24.50 21.42 4 52011 0 64446717
Nightmare 24.43 21.42 53 51962 20940 64425777
Pancreatitis 24.01 21.42 9 52006 59598 64387119
Dyspnoea exertional 23.82 21.42 15 52000 73715 64373002
Oxygen saturation decreased 23.68 21.42 31 51984 107145 64339572
Facial discomfort 23.60 21.42 6 52009 48 64446669
Encephalopathy 23.49 21.42 9 52006 58810 64387907
Skin indentation 23.46 21.42 5 52010 16 64446701
Drooling 23.36 21.42 25 51990 5294 64441423
Eyelids pruritus 23.30 21.42 11 52004 621 64446096
Ear discomfort 23.20 21.42 29 51986 7251 64439466
Haemorrhage 23.18 21.42 18 51997 79333 64367384
Procedural anxiety 23.02 21.42 11 52004 638 64446079
Haematuria 22.94 21.42 10 52005 60461 64386256
Injection site granuloma 22.78 21.42 6 52009 56 64446661
Blood pressure systolic increased 22.53 21.42 6 52009 49447 64397270
Muscle atrophy 22.18 21.42 33 51982 9725 64436992
Pancreatitis acute 21.94 21.42 4 52011 42851 64403866
White blood cell count increased 21.93 21.42 13 52002 66001 64380716
Gastrointestinal disorder 21.89 21.42 24 51991 89685 64357032
Gamma-glutamyltransferase increased 21.88 21.42 6 52009 48504 64398213
Vestibular migraine 21.71 21.42 7 52008 139 64446578
Serotonin syndrome 21.62 21.42 3 52012 39279 64407438
Pericardial effusion 21.60 21.42 3 52012 39251 64407466
Cutis laxa 21.57 21.42 7 52008 142 64446575
Dysarthria 21.52 21.42 100 51915 59306 64387411

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
MeSH PA D065087 Acetylcholine Release Inhibitors
MeSH PA D018678 Cholinergic Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D009465 Neuromuscular Agents
MeSH PA D009498 Neurotoxins
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D009676 Noxae
MeSH PA D018373 Peripheral Nervous System Agents
FDA PE N0000175731 Neuromuscular Blockade
FDA MoA N0000175770 Acetylcholine Release Inhibitors
FDA EPC N0000175771 Acetylcholine Release Inhibitor
FDA EPC N0000193962 Neuromuscular Blocker

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Rhytidectomy of glabellar frown lines indication 14667004
Urge urinary incontinence indication 87557004
Urinary frequency indication 162116003
Lower limb spasticity indication 394679006
Upper limb spasticity indication 394680009
Neurogenic bladder indication 398064005
Overactive bladder indication 786457000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Synaptosomal-associated protein 25 Cytosolic other BLOCKER SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
CHEBI:3160 CHEBI
CHEMBL4297862 ChEMBL_ID
D00783 KEGG_DRUG
C545476 MESH_SUPPLEMENTAL_RECORD_UI
93384-43-1 SECONDARY_CAS_RN
DB00083 DRUGBANK_ID
E211KPY694 UNII
1000104 RXNORM
27317 MMSL
4295 MMSL
d01227 MMSL
d07669 MMSL
108890005 SNOMEDCT_US
427412002 SNOMEDCT_US
703368006 SNOMEDCT_US
772950004 SNOMEDCT_US
4020561 VANDF
4030130 VANDF
C0006050 UMLSCUI
CHEMBL2108035 ChEMBL_ID
013287 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
BOTOX HUMAN PRESCRIPTION DRUG LABEL 1 0023-1145 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 [USPU] INTRADERMAL BLA 30 sections
BOTOX Cosmetic HUMAN PRESCRIPTION DRUG LABEL 1 0023-3919 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 [USPU] INTRAMUSCULAR BLA 30 sections
BOTOX HUMAN PRESCRIPTION DRUG LABEL 1 0023-3921 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 200 [USPU] INTRADERMAL BLA 30 sections
BOTOX Cosmetic HUMAN PRESCRIPTION DRUG LABEL 1 0023-9232 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 [USPU] INTRAMUSCULAR BLA 30 sections
Xeomin HUMAN PRESCRIPTION DRUG LABEL 1 0259-1605 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 [USPU] INTRAMUSCULAR BLA 31 sections
Xeomin HUMAN PRESCRIPTION DRUG LABEL 1 0259-1610 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 [USPU] INTRAMUSCULAR BLA 31 sections
Xeomin HUMAN PRESCRIPTION DRUG LABEL 1 0259-1620 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 200 [USPU] INTRAMUSCULAR BLA 31 sections
Xeomin HUMAN PRESCRIPTION DRUG LABEL 1 0259-4110 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 [USPU] INTRAMUSCULAR BLA 31 sections
Xeomin HUMAN PRESCRIPTION DRUG LABEL 1 0259-4150 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 [USPU] INTRAMUSCULAR BLA 31 sections
Dysport HUMAN PRESCRIPTION DRUG LABEL 1 0299-5962 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 300 U INTRAMUSCULAR BLA 33 sections
Dysport HUMAN PRESCRIPTION DRUG LABEL 1 0299-5962 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 300 U INTRAMUSCULAR BLA 33 sections
Dysport HUMAN PRESCRIPTION DRUG LABEL 1 15054-0500 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 U INTRAMUSCULAR BLA 31 sections
Dysport HUMAN PRESCRIPTION DRUG LABEL 1 15054-0530 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 300 U INTRAMUSCULAR BLA 31 sections
Xeomin HUMAN PRESCRIPTION DRUG LABEL 1 46783-160 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 [USPU] INTRAMUSCULAR BLA 31 sections
Xeomin HUMAN PRESCRIPTION DRUG LABEL 1 46783-161 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 [USPU] INTRAMUSCULAR BLA 31 sections
Xeomin HUMAN PRESCRIPTION DRUG LABEL 1 46783-165 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 [USPU] INTRAMUSCULAR BLA 31 sections
Jeuveau HUMAN PRESCRIPTION DRUG LABEL 1 72301-595 POWDER 100 [USPU] INTRAMUSCULAR BLA 28 sections